KB-1109

BMS986156-hIgG1

45183

Home » Antibodies » BMS986156-hIgG1

Background of BMS986156-hIgG1

GITR (a transmembrane receptor located on T lymphocytes) is largely not expressed in naïve T cells, but rather becomes increasingly expressed with T-cell activation. It was hypothesized that antibodies targeting GITR could potentially activate costimulatory pathways, thereby synergizing effectively with inhibitors of both PD-1 and PD-L1 within the tumor microenvironment. BMS-986156 is an immunoglobulin G subclass 1 agonist monoclonal antibody targeting the GITR.

Specifications

Catalog Number	KB-1109
Antibody Name	BMS986156-hIgG1
Isotype	Human IgG1,kappa
Target	GITR
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 9;12(10):e009975.
Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol. 2020 Jan 1;6(1):100-107.